文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿昔洛韦对高载量单纯疱疹病毒复制的呼吸机相关性肺炎患者生存的影响

Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication.
PubMed 文献 · Crit Care · 2020-01-10
一句话结论对呼吸机相关性肺炎、抗生素治疗失败且呼吸道HSV载量>10^5拷贝/mL的患者,阿昔洛韦治疗与ICU生存时间延长及循环、氧合功能改善相关。

研究回顾性比较未治疗与阿昔洛韦治疗的高载量(>10^5 HSV拷贝/mL)和低载量(10^3-10^5拷贝/mL)HSV复制患者的ICU生存时间、临床参数和影像学表现。共识别57例低载量和69例高载量患者。高载量患者中抗生素治疗应答者更少(12% vs 40%,p=0.001)。仅在高载量患者中,阿昔洛韦改善中位ICU生存(8天 vs 22天,p=0.014)并与ICU死亡风险比显著降低相关(HR=0.31,95%CI 0.11-0.92,p=0.035)。高载量患者治疗期间循环和肺氧合功能显著改善:去甲肾上腺素平均剂量从0.05降至0.02 μg/kg/min(第0天至第6天,p=0.049),中位PaO2/FiO2从187升至241(第3天至第7天,p=0.02),胸片表现也显著改善(p<0.001)。

要点

  • 高载量HSV(>10^5拷贝/mL)VAP患者抗生素应答率仅12%,显著低于低载量患者的40%(p=0.001)。
  • 仅在高载量患者中,阿昔洛韦与中位ICU生存延长相关(8天 vs 22天,p=0.014),ICU死亡HR=0.31(95%CI 0.11-0.92,p=0.035)。
  • 高载量患者阿昔洛韦治疗期间去甲肾上腺素平均剂量从0.05降至0.02 μg/kg/min(第0天至第6天,p=0.049)。
  • 高载量患者阿昔洛韦治疗期间中位PaO2/FiO2从187升至241(第3天至第7天,p=0.02),胸片表现显著改善(p<0.001)。
  • 作者认为,在这一高度选择的人群中,HSV可能起致病作用。

适用人群与场景

  • 机械通气的ICU患者,呼吸机相关性肺炎且抗生素治疗失败,呼吸道分泌物(支气管肺泡灌洗液或气管抽吸物)经定量实时PCR检出HSV复制。
  • 按HSV载量分层:高载量(>10^5拷贝/mL)和低载量(10^3-10^5拷贝/mL)。

诊断标准与关键阈值

  • 高病毒载量定义为HSV >10^5拷贝/mL,低病毒载量定义为10^3-10^5拷贝/mL,检测方法为定量实时PCR。

处置流程与药物剂量

  • 高载量患者接受阿昔洛韦治疗;原文未报告阿昔洛韦的剂量、给药途径、频次和疗程。

研究设计与关键结果

  • 回顾性比较未治疗与阿昔洛韦治疗的高载量和低载量HSV复制患者,共识别57例低载量和69例高载量患者。
  • 高载量患者抗生素治疗应答率12%(vs 低载量40%,p=0.001)。
  • 仅在高载量患者中,阿昔洛韦改善中位ICU生存(8天 vs 22天,p=0.014),并与ICU死亡风险比降低相关(HR=0.31,95%CI 0.11-0.92,p=0.035)。
  • 高载量患者阿昔洛韦治疗期间去甲肾上腺素平均剂量从0.05降至0.02 μg/kg/min(第0天至第6天,p=0.049)。
  • 高载量患者阿昔洛韦治疗期间中位PaO2/FiO2从187升至241(第3天至第7天,p=0.02)。
  • 高载量患者阿昔洛韦治疗期间胸片表现显著改善(p<0.001)。

证据类型、等级与局限

  • 研究类型:回顾性比较研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对呼吸机相关性肺炎、抗生素治疗失败且呼吸道HSV载量>10^5拷贝/mL的患者,阿昔洛韦治疗与ICU生存时间延长及循环、肺氧合功能改善相关。
  • 作者认为,HSV可能在这一高度选择的人群中起致病作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high proportion of ventilated intensive care unit (ICU) patients. However, the clinical significance remains poorly defined. We investigated whether patients with ventilator-associated pneumonia not responding to antibiotics and in whom high levels of HSV could be detected in respiratory secretions benefit from acyclovir treatment.

METHODS: Respiratory secretions (bronchoalveolar lavage fluid or tracheal aspirates) were tested for HSV replication by quantitative real-time PCR. ICU survival times, clinical parameters, and radiographic findings were retrospectively compared between untreated and acyclovir treated patients with high (> 105 HSV copies/mL) and low (103-105 HSV copies/mL) viral load.

RESULTS: Fifty-seven low and 69 high viral load patients were identified. Fewer patients with high viral load responded to antibiotic treatment (12% compared to 40% of low load patients, p = 0.001). Acyclovir improved median ICU survival (8 vs 22 days, p = 0.014) and was associated with a significantly reduced hazard ratio for ICU death (HR = 0.31, 95% CI 0.11-0.92, p = 0.035) in high load patients only. Moreover, circulatory and pulmonary oxygenation function of high load patients improved significantly over the course of acyclovir treatment: mean norepinephrine doses decreased from 0.05 to 0.02 μg/kg body weight/min between days 0 and 6 of treatment (p = 0.049), and median PaO2/FiO2 ratio increased from 187 to 241 between day 3 and day 7 of treatment (p = 0.02). Chest radiographic findings also improved significantly (p < 0.001).

CONCLUSIONS: In patients with ventilator-associated pneumonia, antibiotic treatment failure, and high levels of HSV replication, acyclovir treatment was associated with a significantly longer time to death in the ICU and improved circulatory and pulmonary function. This suggests a causative role for HSV in this highly selected group of patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Schuierer L, Gebhard M, Ruf HG, et al. Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication. Crit Care. 2020. PMID: 31924246. doi:10.1186/s13054-019-2701-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。